Improved delivery system for celastrol-loaded magnetic Fe3O4/α-Fe2O3 heterogeneous nanorods: HIF-1α-related apoptotic effects on SMMC-7721 cell

Magnetic self-assembled label-free electrochemical biosensor based on Fe3O4/α-Fe2O3 heterogeneous nanosheets for the detection of Tau proteins

A type of electrochemical biosensors based on magnetic Fe3O4/α-Fe2O3 heterogeneous nanosheets was constructed to detect Tau proteins for early diagnosis and intervention therapy of Alzheimer's disease (AD). Firstly, Fe3O4/α-Fe2O3 heterogeneous nanosheets were fabricated as the substrate to realize magnetic self-assembly and magnetic separation to improve current response, and Fe3O4/α-Fe2O3@Au-Apt/ssDNA/MCH biosensors were successfully constructed through the reduction process of chloroauric acid, the immobilizations of aptamer (Apt) and ssDNA, and the intercept process of 6-Mercapto-1-hexanol (MCH); the construction process of the electrochemical biosensor was monitored using Cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS), and the factors affecting the current response of this sensor (concentration of Fe3O4/α-Fe2O3@Au and Apt/ssDNA, incubation temperature and time of Tau) were explored and optimized using differential pulse voltammetry (DPV). Analyzing the performance of this sensor under optimal conditions, the linear range was finally obtained to be 0.1 pg/mL-10 ng/mL, the limit of detection (LOD) was 0.08 pg/mL, and the limit of quantification (LOQ) was 0.28 pg/mL. The selectivity, reproducibility and stability of the biosensors were further investigated, and in a really sample analysis using human serum, the recoveries were obtained in the range of 93.93 %-107.39 %, with RSD ranging from 1.05 % to 1.94 %.

Role and uptake of metal-based nanoconstructs as targeted therapeutic carriers for rheumatoid arthritis

Rheumatoid Arthritis (RA) is a chronic autoimmune systemic inflammatory disease that affects the joints and other vital organs and diminishes the quality of life. The current developments and innovative treatment options have significantly slowed disease progression and improved their quality of life. Medicaments can be delivered to the inflamed synovium via nanoparticle systems, minimizing systemic and undesirable side effects. Numerous nanoparticles such as polymeric, liposomal, and metallic nanoparticles reported are impending as a good carrier with therapeutic properties. Other issues to be considered along are nontoxicity, nanosize, charge, optical property, and ease of high surface functionalization that make them suitable carriers for drug delivery. Metallic nanoparticles (MNPs) (such as silver, gold, zinc, iron, titanium oxide, and selenium) not only act as good carrier with desired optical property, and high surface modification ability but also have their own therapeutical potential such as anti-oxidant, anti-inflammatory, and anti-arthritic properties, making them one of the most promising options for RA treatment. Regardless, cellular uptake of MNPs is one of the most significant criterions for targeting the medication. This paper discusses the numerous interactions of nanoparticles with cells, as well as cellular uptake of NPs. This review provides the mechanistic overview on MNPs involved in RA therapies and regulation anti-arthritis response such as ability to reduce oxidative stress, suppressing the release of proinflammatory cytokines and expression of LPS induced COX-2, and modulation of MAPK and PI3K pathways in Kuppfer cells and hepatic stellate cells. Despite of that MNPs have also ability to regulates enzymes like glutathione peroxidases (GPxs), thioredoxin reductases (TrxRs) and act as an anti-inflammatory agent.

Fabrication of magneticα-Fe2O3/Fe3O4heterostructure nanorods via the urea hydrolysis-calcination process and their biocompatibility with LO2and HepG2cells

β-FeOOH nanorods were prepared via the urea hydrolysis process with the average length of 289.1 nm and average diameter of 61.2 nm, while magneticα-Fe2O3/Fe3O4heterostructure nanorods were prepared via the urea calcination process withβ-FeOOH nanorods as precursor, and the optimum conditions were the calcination temperature of 400 °C, the calcination time of 2 h, theβ-FeOOH/urea mass ratio of 1:6. The average length, diameter, and the saturation magnetization of the heterostructure nanorods prepared under the optimum conditions were 328.8 nm, 63.4 nm and 42 emu·g-1, respectively. The Prussian blue test demonstrated that the heterostructure nanorods could be taken up by HepG2 cells, and cytotoxicity tests proved that the heterostructure nanorods had no significant effect on the viabilities of LO2 and HepG2 cells within 72 h in the range of 100-1600μg·ml-1. Therefore, magneticα-Fe2O3/Fe3O4heterostructure nanorods had better biocompatibility with LO2 and HepG2 cells.

Construction of targeted delivery system for curcumin loaded on magnetic α-Fe2O3/Fe3O4 heterogeneous nanotubes and its apoptosis mechanism on MCF-7 cell

In this work, the magnetic α-Fe₂O₃/Fe₃O₄ heterogeneous nanotubes were successfully prepared by solvent hydrothermal-controlled calcination method. The effects of additive concentration, hydrothermal temperature and time on morphology of products were investigated. The α-Fe₂O₃/Fe₃O₄ nanotubes with a saturation magnetization of 50 emu/g were prepared calcinated at 600 °C for 4 h using 0.8 g of glucose. Their average length, the outer and inner diameters were around 240 nm, 178 nm and 145 nm, respectively. The α-Fe₂O₃/Fe₃O₄ heterogeneous nanotubes coated with water-soluble liposome were applied for targeted delivery of curcumin. The release of curcumin inside the hollow structure of the nanocomposites could be triggered and effectively sustained represented a process of slow release. The encapsulation efficiency of curcumin in the α-Fe₂O₃/Fe₃O₄-CUR@LIP nanocomposites reached 82.1 ± 0.9%. MTT assays demonstrated that blank carriers had excellent biocompatibility and application of magnetic field significantly elevated the cytotoxicity of α-Fe₂O₃/Fe₃O₄-CUR@LIP nanocomposites on MCF-7 cell. Electrochemical experiment and Prussian blue staining indicated that the α-Fe₂O₃/Fe₃O₄@LIP nanocomposites could aggregate in cells to promote the internalization of curcumin. Magnetic α-Fe₂O₃/Fe₃O₄-CUR@LIP nanocomposites and curcumin enhanced the expression of reactive oxygen species in MCF-7 cells and induced apoptosis by fluorescence detection. Flow cytometry and western blot verified that the α-Fe₂O₃/Fe₃O₄@LIP nanocomposites under magnetic field enhanced cells late-apoptosis by adjusting the expression of apoptosis-related proteins.

Loading drugs into liposomes by temperature up-down cycle procedure with controllable results fitting prediction by mathematical and thermodynamic process

Liposomes are a useful carrier for delivering drugs but rarely make a poorly water-soluble drug (PWSD) realize its therapeutic potential. A key barrier lies in that, by conventional methods, PWSD is mainly loaded just in liposome bilayer membranes, which rarely provide sufficient room to accommodate drugs satisfying clinical therapy. In this investigation, a novel procedure of temperature up-down cycle (TUDC) was developed for loading PWSDs into the liposome interiors instead of bilayer membranes to hold enough agents. In particular, the TUDC procedure renders PWSDs such as curcumin (Cur) entrapment purposely controllable, as evidenced by the encapsulation efficiency (EE) of Cur varies nearly from 0% to 100% in response to changes the determinant factors of the procedure. In addition, several mathematical equations that could calculate the loading efficiency by TUDC were established and proved, when combined with thermodynamic process, able to successfully predict the loading results through including thermodynamic parameters, such as temperature and deduced drug solubility, thus remarkably cutting down the laborious experiments and enhancing liposome development efficiency. Cryo-TEM, SAXS, XRD and DSC tests proved that TUDC is feasible to load a PWSD into PEG-liposomes but rendering the drug in the amorphous state. Thus, the novel TUDC procedure and the established mathematical and thermodynamic process may provide a useful tool to promote the development of liposome products.

Celastrol in cancer therapy: Recent developments, challenges and prospects

Cancer is one of the world's biggest healthcare burdens and despite the current advancements made in treatment plans, the outcomes for oncology patients have yet to reach their full potential. Hence, there is a pressing need to develop novel anti-cancer drugs. A popular drug class for research are natural compounds, due to their multi-targeting potential and enhanced safety profile. One such promising natural bioactive compound derived from a vine, Tripterygium wilfordii is celastrol. Pre-clinical studies revolving around the use of celastrol have revealed positive pharmacological activities in various types of cancers, thus suggesting the chemical's potential anti-cancerous effects. However, despite the numerous preclinical studies carried out over the past few decades, celastrol has not reached human trials for cancer. In this review, we summarize the mechanisms and therapeutic potentials of celastrol in treatment for different types of cancer. Subsequently, we also explore the possible reasons hindering its development for human use as cancer therapy, like its narrow therapeutic window and poor pharmacokinetic properties. Additionally, after critically analysing both in vitro and in vivo evidence, we discuss about the key pathways effected by celastrol and the suitable types of cancer that can be targeted by the natural drug, thus giving insight into future directions that can be taken, such as in-depth analysis and research of the druggability of celastrol derivatives, to aid the clinical translation of this promising anti-cancer lead compound.